NCT01067716已完成不适用
A Prospective Study to Evaluate the Performance and Acceptability of Advanced Variable Spot Scanning (AVSS) Ablations With the STAR S4 IR® Excimer Laser System
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 150
- 试验地点
- 10
- 主要终点
- Percent of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better
研究概览
简要总结
The results of this trial will demonstrate that AVSS software performs as intended and is acceptable in a clinical setting.
详细描述
LASIK treatment across the range of myopia with or without astigmatism, hyperopia with or without astigmatism, and mixed astigmatism.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, of any race, and at least 21 years old at the time of the pre-operative examination and signing the consent form.
- •The refractive error, based on manifest refraction at the spectacle plane, of: MRSE up to -15.00 D with manifest cylinder between 0.00 and -6.00 D; MRSE up to +7.00 D, with manifest cylinder between 0.00 and 6.00 D; or Manifest cylinder (from 1.0 to 6.0 D) greater than the magnitude of sphere, and the manifest cylinder and sphere have opposite signs.
- •BSCVA of 20/20 or better.
- •UCVA of 20/40 or worse.
- •Manifest refraction sphere within ± 0.75 D of cycloplegic refraction sphere (at the same vertex distance).
- •Anticipated post-operative stromal bed thickness of at least 250 microns, based on pre-operative central corneal pachymetry minus the maximum treatment depth to be ablated and the intended flap thickness, and confirmed by intra-operative central corneal pachymetry.
- •Anticipated post-operative keratometry value (based on pre-operative manifest refraction and keratometry) that is appropriate.
- •A stable refractive error, based on an exam (or prescription) at least 12 months prior to the pre-operative examination and as compared to the pre-operative manifest refraction
- •Subjects who have worn a contact lens in the operative eye must discontinue lens wear at least three (3) consecutive weeks prior to the pre-operative examination. If, upon review of pre-operative measurements, the Investigator determines that the corneal topography is within normal limits, surgery may be scheduled (within 60 days), with no contact lens wear permitted prior to the surgery.
- •Willing and capable of returning for follow-up examinations for the duration of the study (6 months).
排除标准
- •Women who are pregnant, breast-feeding, or intend to become pregnant over the course of the study, as determined by verbal inquiry.
- •Concurrent use of topical or systemic medications that may impair healing, including but not limited to: antimetabolites, isotretinoin (Accutane®) within 6 months of treatment, and amiodarone hydrochloride (Cordarone®) within 12 months of treatment.
- •History of any of the following medical conditions, or any other condition that could affect wound healing: collagen vascular disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or herpes simplex, endocrine disorders (including, but not limited to unstable thyroid disorders and diabetes), lupus, and rheumatoid arthritis.
- •Subjects with a cardiac pacemaker or implanted defibrillator.
- •History of prior intraocular or corneal surgery (including cataract extraction), active ophthalmic disease or abnormality (including, but not limited to, symptomatic blepharitis, recurrent corneal erosion, dry eye syndrome, neovascularization > 1mm from limbus), retinal detachment/repair, clinically significant lens opacity, clinical evidence of trauma, corneal opacity within the central 9 mm, at risk for developing strabismus, or with evidence of glaucoma or propensity for narrow angle glaucoma.
- •Evidence of keratoconus, corneal dystrophy or irregularity, or abnormal videokeratography.
- •Known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course.
- •Subjects with one eye that does not meet all inclusion criteria and does not fall within approved indications for treatment using the VISX® STAR S4 IR® Excimer Laser.
- •Participation in any other clinical study.
结局指标
主要结局
Percent of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better
时间窗: 1 Year
次要结局
未报告次要终点
研究者
研究点 (10)
Loading locations...
相似试验
已完成
不适用
Performance and Acceptability of iDesignRefractive ErrorNCT01220466Abbott Medical Optics77
招募中
不适用
Proeftuin Integrative MedicinePatients with chronic musculoskeletal pain, (Osteo)arthritis, rheumatoid arthritis, fibromyalgia, low back pain, neck pain, tennis elbow or golfers arm, non-specific joint complaints, reuma, artrose, fibromyalgie, klachten bewegingsapparaatNL-OMON27322268
已完成
不适用
Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer PatientsBreakthrough Cancer PainNCT03895762A.Menarini Asia-Pacific Holdings Pte Ltd143
已完成
不适用
A novel neuromodulation technique in the treatment of chronic pain.NL-OMON26726Spinal Modulation, Inc.1135 O'Brien Dr.Menlo Park, CA 94025USA30
已完成
不适用
SureScan Post-Approval StudyBradycardiaNCT01299675Medtronic2,483